A phase 2, randomized, double-blind, placebo-controlled study to evaluate the BIA 28-6156 in subjects with Parkinson's Disease with a pathogenic variant in the glucocerebrosidase (GBA1)
Topic / Pathology
- Parkinson's Disease
Objectives
To assess the efficacy of BIA 28-6156 in delaying meaningful clinical motor progression in subjects with Parkinson's disease who have a pathogenic variant in the GBA1 gene as assessed by the MDS-UPDRS Part II
Sponsor
BIAL
Status
Recruiting
